Telomerase reverse transcriptase (TERT) promoter mutations have been detected in several human cancers, including thyroid cancer [1], and have been reported to be an independent poor prognostic factor in the recurrence and cancer-specific survival (CSS) of patients with differentiated thyroid cancer (DTC) [2,3]. This evidence concerns the gene TERT and thyroid cancer.